Bezafibrate can be a new treatment option for mitochondrial fatty acid oxidation disorders: Evaluation by in vitro probe acylcarnitine assay

Molecular Genetics and Metabolism

Volumn 107, Issue 1-2, 2012, Pages 87-91

  Yamaguchi, Seiji ^a   Li, Hong ^a,b   Purevsuren, Jamiyan ^a   Yamada, Kenji ^a   Furui, Midori ^a   Takahashi, Tomoo ^a   Mushimoto, Yuichi ^a   Kobayashi, Hironori ^a   Hasegawa, Yuki ^a   Taketani, Takeshi ^a   Fukao, Toshiyuki ^c   Fukuda, Seiji ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b AFFILIATED HOSPITAL OF NINGXIA MEDICAL UNIVERSITY   (China)

^c GIFU UNIVERSITY   (Japan)

Author keywords

Bezafibrate; Hypolipidemic drug; In vitro probe acylcarnitine assay; Mitochondrial fatty acid oxidation disorder; New treatment; Peroxisome proliferation activator receptor

Indexed keywords

ACYLCARNITINE; BEZAFIBRATE; CARNITINE PALMITOYLTRANSFERASE; FATTY ACID; LONG CHAIN ACYL COENZYME A DEHYDROGENASE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE;

ARTICLE; ASSAY; CARNITINE PALMITOYLTRANSFERASE II DEFICIENCY; CASE REPORT; CELL CULTURE; CHILD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CULTURE MEDIUM; DISORDERS OF MITOCHONDRIAL FUNCTIONS; FATTY ACID OXIDATION; FIBROBLAST; HUMAN; IN VITRO PROBE ACYLCARNITINE ASSAY; IN VITRO STUDY; MALE; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY; MULTIPLE ACYL COA DEHYDROGENASE DEFICIENCY; PRESCHOOL CHILD; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; THERAPY EFFECT; VERY LONG CHAIN ACYL COENZYME A DEHYDROGENASE DEFICIENCY;

BEZAFIBRATE; CARBOXYLIC ACIDS; CARNITINE; CELLS, CULTURED; FATTY ACIDS; FIBROBLASTS; HUMANS; MITOCHONDRIAL DISEASES; OXIDATION-REDUCTION;

EID: 84866151057     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2012.07.004     Document Type: Article

References (22)

1. McCabe L.L., McCabe E.R.B. Expanded newborn screening: implications for genomic medicine. Annu. Rev. Med. 2008, 59:163-175.
2. Wilcken B., Haas M., Joy P., Wiley V., Bowling F., Carpenter K., Christodoulou J., Cowley D., Ellaway C., Fletcher J., Kirk E.P., Lewis B., McGill J., Peters H., Pitt J., Ranieri E., Yaplito-Lee J., Boneh A. Expanded newborn screening: outcome in screened and unscreened patients at age 6 years. Pediatrics 2009, 124:e241-e248.
3. Rinaldo P., Matern D., Bennett M.J. Fatty acid oxidation disorders. Annu. Rev. Physiol. 2002, 64:477-502.
4. Kompare M., Rizzo W.B. Mitochondrial fatty-acid oxidation disorders. Semin. Pediatr. Neurol. 2008, 15:140-149.
5. Bennett M.J. Pathophysiology of fatty acid oxidation disorders. J. Inherit. Metab. Dis. 2010, 33:533-537.
6. Andresen B.S., Olpin S., Poorthuis B.J., Scholte H.R., Vianey-Saban C., Wanders R., Ijlst L., Morris A., Pourfarzam M., Bartlett K., Baumgartner E.R., deKlerk J.B., Schroeder L.D., Corydon T.J., Lund H., Winter V., Bross P., Bolund L., Gregersen N. Clear correlation of genotype with disease phenotype in very-long-chain acyl-CoA dehydrogenase deficiency. Am. J. Hum. Genet. 1999, 64:479-494.
7. Okun J.G., Kolker S., Schulze A., Kohlmuller D., Olgemoller K., Linder M., Hoffmann G.F., Wanders R.J.A., Mayatepek E. A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency. Biochim. Biophys. Acta 2002, 1584:91-98.
8. Sim K.G., Carpenter K., Hammond J., Christodoulou J., Wilcken B. Quantitative fibroblast acylcarnitine profiles in mitochondrial fatty acid beta-oxidation defects: phenotype/metabolite correlations. Mol. Genet. Metab. 2002, 76:327-334.
9. Aoyama T., Peters J.M., Iritani N., Nakajima T., Furihata K., Hashimoto T., Gonzalez F.J. Altered constitutive expression of fatty acid-metabolizing enzymes in mice lacking the peroxisome proliferator-activated receptor alpha (PPARalpha). J. Biol. Chem. 1998, 273:5678-5684.
10. Djouadi F., Bonnefont J.P., Thuillier L., Droin V., Khadom N., Munnich A., Bastin J. Correction of fatty acid oxidation I carnitine palmitoyl transferase 2-deficient cultured skin fibroblasts by bezafibrate. Pediatr. Res. 2003, 54:446-451.
11. Gobin-Limballe S., Djouadi F., Aubey F., Olpin S., Andresen B.S., Yamaguchi S., Mandel H., Fukao T., Ruiter J.P., Wanders R.J., McAndrew R., Kim J.J., Bastin J. Genetic basis for correction of very-long-chain acyl-coenzyme A dehydrogenase deficiency by bezafibrate in patient fibroblasts: toward a genotype-based therapy. Am. J. Hum. Genet. 2007, 81:1133-1143.
12. Lopriore E., Gemke R.J., Verhoeven N.M., Jakobs C., Wanders R.J., Roeleveld-Versteeg A.B., Poll-The B.T. Carnitine-acylcarnitine translocase deficiency: phenotype, residual enzyme activity and outcome. Eur. J. Pediatr. 2001, 160:101-104.
13. Li H., Fukuda S., Hasegawa Y., Kobayashi H., Purevsuren J., Mushimoto Y., Yamaguchi S. Effect of heat stress and bezafibrate on mitochondrial β-oxidation: comparison between cultured cells from normal and mitochondrial fatty acid oxidation disorder children using in vitro probe acylcarnitine profiling assay. Brain Dev. 2010, 32:362-370.
14. Yamaguchi S., Iga M., Kimura M., Suzuki Y., Shimozawa N., Fukao T., Kondo N., Tazawa Y., Orii T. Urinary organic acids in peroxisomal disorders: a simple screening method. J. Chromatogr. B 2001, 758:81-86.
15. Spiekerkoetter U., Lindner M., Santer R., Grotzke M., Baumgartner M.R., Boehles H., Das A., Haase C., Hennermann J.B., Karall D., de Klerk H., Knerr I., Koch H.G., Plecko B., Röschinger W., Schwab K.O., Scheible D., Wijburg F.A., Zschocke J., Mayatepek E., Wendel U. Management and outcome in 75 individuals with long-chain fatty acid oxidation defects: results from a workshop. J. Inherit. Metab. Dis. 2009, 32:488-497.
16. Spiekerkoetter U., Bastin J., Gillingham M., Morris A., Wijburg F., Wilcken B. Current issues regarding treatment of mitochondrial fatty acid oxidation disorders. J. Inherit. Metab. Dis. 2010, 33:555-561.
17. Laforêt P., Vianey-Saban C. Disorders of muscle lipid metabolism: diagnostic and therapeutic challenges. Neuromuscul. Disord. 2010, 20:693-700.
18. Vockley J., Whiteman D.A. Defects of mitochondrial beta-oxidation: a growing group of disorders. Neuromuscul. Disord. 2002, 12:235-246.
19. Djouadi F., Aubey F., Schlemmer D., Ruiter J.P., Wanders R.J., Strauss A.W., Bastin J. Bezafibrate increases very-long-chain acyl-CoA dehydrogenase protein and mRNA expression in deficient fibroblasts and is a potential therapy for fatty acid oxidation disorders. Hum. Mol. Genet. 2005, 14:2695-2703.
20. Bonnefont J.P., Bastin J., Laforet P., Aubey F., Mogenet A., Romano S., Ricquier D., Gobin-Limballe S., Vassault A., Behin A., Eymard B., Bresson J.L., Djouadi F. Long-term follow-up of bezafibrate treatment in patients with the myopathic form of carnitine palmitoyltransferase 2 deficiency. Clin. Pharmacol. Ther. 2010, 88:101-108.
21. Bonnefont J.P., Bastin J., Behin A., Djouadi F. Bezafibrate for treatment of an inborn mitochondrial b-oxidation defect. N. Engl. J. Med. 2009, 360:838-840.
22. Bastin J., Lopes-Costa A., Djouadi F. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts. Hum. Mol. Genet. 2011, 20:2048-2057.